When: Pullback to $110-112 with 10 EMA and Bollinger middle holding, RSI resetting toward 55-60, MACD histogram stabilizing

Then: Add 50% of intended increment (~1.0% weight); stop at $109.50

When: Price at $105-107 ONLY if Q3 2026 earnings validate $6.06 EPS path and D/E trends toward 55%

Then: Add 25% of intended increment (~0.5% weight); otherwise pass and reassess

HOLD current position; do not add at $114; any additions conditional on acquisition and debt validation; enforce position sizing and interim technical risk triggers

• 18.8x forward P/E based on $6.06 EPS forecast; if EPS delivers 90% of estimate ($5.45), implied P/E rises to ~20.9x
• Goodwill increased 47% from ~$24B to $35.2B; other intangibles up ~$12.3B; goodwill/intangibles now ~48% of total assets with negative tangible book value
• Debt increased ~$20B; net debt up ~$22.8B; debt-to-equity rose from ~27% to 65%
• Q2 operating income declined ~21% YoY to ~$1.345B from $1.693B; sequential decline ~35%; net margin fell to ~9.6% from 12.8%
• TTM free cash flow ~$7.21B yielding ~3.65%; annual dividends ~$4.1B with buybacks and $670M NEC settlement create narrower capital allocation margin
• ABT closed at $114.10, only $0.41 (~0.4%) above 10-day EMA; ATR $2.51 (~2.2% of price); MACD 4.098 just below signal 4.115
• Risk-reward poor: entry at $111-$112 with $113 stop places stop above entry; $117.34 breakout risks ~3.7% for <1% upside to first resistance at $118.29
• $96 hard stop represents ~15.9% downside from $114 requiring 18.9% recovery to break even
• Catalyst stack overstated: Libre Duo FDA approval ≠ commercial revenue; DexCom replication claim unsupported; MiniMed incremental and unquantified; settlement is real cash outflow not 'price of admission'
• Sentiment only mildly bullish at 6.8/10; 13% gain in 30 days and 33% in 90 days suggest catalysts partially reflected in price
• Macro support limited: 87% probability of no rate cuts keeps debt costs elevated; beta 0.58 doesn't cap company-specific risks
• Conditional additions below $105-$100 require: stable/improving FCF, visible debt reduction, clear acquisition guidance, earnings validation or technical reversal confirmation

→ vs aggressive: 18.8x P/E is not obsolete; $6.06 EPS forecast is not reported EPS—if EPS is only $5.45, P/E becomes 20.9x; upside targets to $125-$130 require multiple expansion, not justified by acquisition alone

→ vs aggressive: Goodwill rose 47%, not tripling; other intangibles ~$12.3B create integration, impairment, and leverage risk, not automatic valuation re-rating

→ vs aggressive: Q2 earnings decline dismissed as 'accounting noise'; revenue +7.8% but operating income -21% YoY and -35% sequentially with net margin contraction to 9.6% from 12.8%

→ vs aggressive: TTM FCF ~$7.21B at 3.65% yield is respectable but not large cushion given $4.1B annual dividends, buybacks, acquisition debt, and $670M settlement

→ vs aggressive: Debt-to-equity surged from 27% to 65%; negative tangible equity is a meaningful warning; acquisition-specific details (target, PPA, synergies, accretion bridge) not disclosed

→ vs aggressive: Technical entry at 10-day EMA with 0.4% margin is not compelling; 8/26 bearish candle on elevated volume is 'support' is premature; proposed risk-reward mechanics are invalid

→ vs aggressive: Citadel 547% position increase heavily influenced by starting size, timing, and portfolio activity—not a guarantee of future returns

→ vs aggressive: Boston Scientific cyber incident is not a fundamental catalyst for ABT; peer misfortune is not a reason to add risk

→ vs aggressive: Macro case (8% recession probability, 87% no rate cuts) is supportive but doesn't protect against litigation, acquisition impairment, product recall, or earnings warning

HOLD existing position with conditional scale-in ladder; add on breakout confirmation ($117.34 on 7M+ volume) or pullback confirmation ($110-112 with 10 EMA support); use Q3 2026 earnings as binary event to validate or invalidate thesis

• Do not add at $114 - entry too close to 8/26 close and stop placement is broken; aggressive analyst's suggestion of adding at $111-112 with $113 stop is worse than doing nothing
• Trigger 1: Breakout above $117.34 on volume >7M shares, add 25% with stop at $113.50, targeting $125-130 for ~3.2-to-1 reward-to-risk
• Trigger 2: Pullback to $110-112 zone with 10 EMA and Bollinger middle as support, confirmed hold, stop below $109.50 for ~2-to-1 reward-to-risk
• Trigger 3: $105-107 only fires if Q3 2026 earnings show deal integration tracking; otherwise let level pass and reassess
• Replace $96 hard stop with trailing stop at 10 EMA or $110.61 once price moves above entry; $96 stop reserved as hard floor for fundamental reassessment
• Q3 2026 earnings in October is the binary event: add on deal integration confirmation, trim/exit on EPS disappointment regardless of price
• 18.8x forward P/E is reasonable for high-quality diversified healthcare compounder vs. Medtronic, Becton Dickinson, Stryker; $125 implies only 20.6x forward earnings
• RSI at 66 is not overbought (healthy mid-range), 50 SMA rising sharply from $88 to $101, 200 SMA reclaimed mid-July
• Macro environment supportive: 87% odds of no rate cuts, 8% recession probability favors defensive quality names
• Interest expense rose $53M ($121M to $174M) but operating income fell $348M sequentially; ~$295M gap unexplained by interest alone - integration costs, amortization, inventory step-up

→ vs aggressive: New 15-19x valuation range argument is unfalsifiable - by that logic every expensive stock is a buy; acquisition deals frequently compress multiples as market demands proof of accretion before rewarding new asset base

→ vs aggressive: Citadel 547% position increase is being overweighted - 547% increase from tiny base is functionally meaningless; $275M increase on hundreds of billions in AUM is a rounding error, not a signal of conviction

→ vs aggressive: Interest expense increase ($53M) explains only ~$53M of the $348M operating income drop; ~$295M unexplained gap is integration costs, amortization step-up, inventory step-up in COGS, not just accounting noise

→ vs aggressive: Momentum names do regularly give clean 10-15% pullbacks - 'momentum names don't typically give clean pullbacks' is empirically false; 33% rally followed by 10% pullback is textbook bull market behavior

→ vs aggressive: Libre Duo TAM creation argument is narrative-driven; FDA approval is necessary but not sufficient; reimbursement, manufacturing scale, prescriber adoption, pricing pressure, and Dexcom competitive response all matter

→ vs conservative: 18.8x forward P/E is reasonable in absolute terms for high-quality diversified healthcare compounder; bear case requires both earnings disappointment AND continued multiple compression - more specific and less likely scenario than implied

→ vs conservative: Technical read is too bearish - RSI at 66 is not overbought, long-term MA alignment (50 SMA rising, 200 SMA reclaimed) is unambiguously bullish; elevated volume on 8/26 could be profit-taking within uptrend rather than distribution

→ vs conservative: Macro argument deserves more weight - 87% no rate cut odds and 8% recession probability is exactly environment where defensive dividend payers with low beta outperform; systematic risk environment unusually benign

→ vs conservative: 'Trim if over limit, hold if within' lacks actionable scenario for adding; defines what not to do but not what 'see' looks like - same trap as aggressive analyst's narrative-driven case, just opposite direction